Company says initial phase of clinical validation trials of NuroPro® AD blood test shows successful diagnoses of different forms of Alzheimer’s, including high-risk patients.

Power3 Medical Products, a leading proteomics company, specializes in the development and commercialization of diagnostic tests for early detection of breast cancer and neurodegenerative diseases. The company is currently conducting a clinical validation study of its NuroPro® blood serum test for Alzheimer’s and Parkinson’s disease in collaboration with Dr. Marwan Sabbagh, the director of clinical research at the Cleo Roberts Center of Clinical Research at the Sun Health Research Institute in Sun City, Arizona.

Woodlands, Texas-based Power 3 recently announced the latest results from the completion of the first phase of clinical validation trials of the NuroPro® PD test, with prospective trials in the United States confirming earlier retrospective studies it started.

NuroPro®, the first blood serum diagnostic test to be available for Alzheimer’s disease, utilizes a panel of blood serum protein biomarkers to determine the probability that a patient has the said degenerative disease.

Power3 said its blood serum biomarker test for Alzheimer’s disease showed successful diagnoses of different forms of Alzheimer’s, a breakthrough seen to advance the diagnostic test’s clinical usefulness.

Commenting on the latest results, CEO Helen R. Park stated in the press release, “Progress thus far of the company’s clinical validation trials confirms our belief that Power3’s NuroPro AD will significantly help physicians make diagnoses and recommend appropriate follow-up and treatment options for their patients, based on the presence of disease. This is a huge advance over only being capable of informing a patient that his or her risk is high.”

According to Power3 president and Chief Scientific Officer Dr. Ira L. Goldknopf, “Roughly half of the Alzheimer’s disease patients possess a gene variant that indicates a higher risk of developing Alzheimer’s disease than the general population. However, roughly 15% of normal individuals also possess this gene variant. There are also other genetic risk factors for Alzheimer’s disease.

“Therefore, unfortunately, positive genetic tests do not inform the patient that they have the disease. They merely let them know they have a higher risk for developing it.”

Dr. Sabbagh had previously said the preliminary results of the Power3’s study look very promising as clinicians around the world look forward to adding a tool to diagnose and treat Alzheimer’s earlier and therefore give the best care to their patients.

The prospective clinical validation trials’ second phase is slated to commence sometime in late 2009, the report said.

About Power3 Medical Products Inc.

Power3 Medical Products (PWRM) is a leader in bio-medical research and the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets, and its diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete phase II clinical validation trials of its blood serum diagnostics for Alzheimer’s and Parkinson’s disease (NuroPro AD and PD), in the fourth quarter of 2009, followed by completion of filing with the FDA. Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), and continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS, Alzheimer’s, and Parkinson’s diseases, breast cancer, and drug resistance.

For additional product and company information, please refer to www.power3medical.com.

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.